LUNG-05: Investigating Chemotherapy Effectiveness for NSCLC Metastatic Patients
University of Illinois at Chicago
Summary
This is a Single arm, Simon's two stage pilot study in which patients with Non-Small Cell Lung Cancer (NSCLC) with metastatic disease 2L and beyond will receive OncoChoice-informed chemotherapy following National Cancer Care Network (NCCN) treatment guidelines on dosage and scheduling for NSCLC FDA approved drugs.
Description
This is a Single arm, Simon's two stage pilot study in which patients with Non-Small Cell Lung Cancer (NSCLC) with metastatic disease 2L and beyond will receive OncoChoice-informed chemotherapy following National Cancer Care Network (NCCN) treatment guidelines on dosage and scheduling for NSCLC FDA-approved drugs. After confirmation of patient eligibility and patient consent receival, patients will undergo biopsy and/or removal of malignant fluids (paracentesis/ thoracentesis/ PleurX catheter) as part of standard of care procedures. Biosamples will be shared in a timely fashion (within 24 hr p…
Eligibility
- Age range
- 18+ years
- Sex
- All
- Healthy volunteers
- No
Inclusion Criteria: * Age ≥ 18 years of age at time of consent * ECOG performance status score of ≤2 * Advanced non-small cell lung cancer to meet histologically confirmed Stage IV NSCLC documented by biopsy. * Patients have received at least 1 prior line of systemic therapy for Stage IV NSCLC, including but not limited to targeted therapy, and are currently candidates for 2L or later SOC chemotherapy. Exceptionally, patients with Stage III NSCLC who have received at least 1 line of systemic therapy may be considered eligible, pending principal investigator approval. * Demonstrates adequate o…
Interventions
- DrugDocetaxel
75 mg/m2 IV over 1-hour Day 1 of each 21-day cycle
- DrugPaclitaxel
135 mg/m2 IV over 3 hours Day 1 of each 21-day cycle
- DrugGemcitabine
1000 mg/m2 IV over 30 minutes on Days 1, 8, and 15 of each 28-day cycle or 1,250 mg/m2 IV over 30 minutes on Days 1 and 8 of each 21 day cycle
- DrugPemetrexed
500 mg/m2 IV over 10 minutes on Day 1 of each 21-day cycle
- DrugVinorelbine
30 mg/m2 IV through a weekly injection over 6-19 minutes on Days 1, 8, and 15 of each 21-day cycle
Location
- University of Illinois Cancer CenterChicago, Illinois